+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Retinoblastoma Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • PDF Icon

    Report

  • 114 Pages
  • February 2024
  • Region: Global
  • Mordor Intelligence
  • ID: 4758242
The Retinoblastoma Treatment Market size is estimated at USD 1.85 billion in 2024, and is expected to reach USD 2.30 billion by 2029, growing at a CAGR of 4.45% during the forecast period (2024-2029).

The COVID-19 pandemic created a significant void in the availability and accessibility of treatment modalities and timely intervention for children with eye cancer. For instance, according to an article published by the Indian Journal of Ophthalmology, in September 2021, the COVID-19-related nationwide lockdown deprived retinoblastoma patients of optimal and timely management, leading to prolonged treatment interruptions. Thus, COVID-19 had an impact on the retinoblastoma treatment market. However, with the decreasing number of COVID-19 cases, the demand for ophthalmic treatment and surgeries increased. For instance, according to an article published by the American Academy of Ophthalmology in November 2021, patients began pouring in with advanced eye cancers in October 2021, and there was an alarming rise in patients that required enucleation. Further, according to the same source, more young children with advanced cases of retinoblastoma were observed in the hospitals in Philadelphia. Hence, with the declining COVID-19 cases, there was an increase in retinoblastoma treatments, thereby fueling market growth, and the same is expected over the forecast period.

Certain factors driving the market growth include remission and the chance of recurrence of retinoblastoma and increasing public awareness of retinoblastoma. For instance, according to an article published by Bone Report, in December 2021, recurrence of retinoblastoma usually occurs within the first few years after treatment. Despite complete tumor regression, delayed relapse of retinoblastoma can occur, predisposing patients to osteosarcoma as a second malignancy. Furthermore, according to an article published by the National Library of Medicine in June 2021, Kaplan-Meier's estimate of tumor recurrence at six months, one year, three years, and five years was 20%, 31%, 68%, and 73%, respectively in 2021. Thus, the remission and the chance of recurrence of retinoblastoma are expected to boost market growth.

Furthermore, every year, to raise awareness, the 2nd week of May is observed as "World Retinoblastoma Awareness Week" around the World. It is an opportunity to raise global awareness of retinoblastoma, a life-threatening eye cancer that is almost exclusively found in young children every year. Hence, rising awareness regarding diseases is projected to boost market growth over the forecast period.

However, the side effects of retinoblastoma surgery and the high cost of treatment in developing countries are likely to hinder market growth over the forecast period.

Retinoblastoma Treatment Market Trends

Non-hereditary Retinoblastoma is Expected to hold a Significant Market Share Over the Forecast Period

In the non-hereditary form of retinoblastoma, typically, only one eye is affected, and there is no family history of the disease. Affected individuals are born with two normal copies of the RB1 gene. An increase in cases of non-hereditary retinoblastoma is expected to drive the market's growth. For instance, according to an article published by Frontiers Media S.A., in November 2022, the incidence of retinoblastoma is approximately 1 in 17,000 live births, with about 8,000 new cases diagnosed each year worldwide where the non-inherited sporadic type accounts for 60-70%. Additionally, according to an article published by the National Library of Medicine, in August 2022, 95% of retinoblastoma cases are sporadic.

Additionally, unilateral retinoblastomas comprise all non-hereditary retinoblastoma. According to an article published by Dove Press Ltd in January 2021, intra-arterial chemotherapy has recently gained wide acceptance in treating unilateral retinoblastoma and reported salvage rates from 66.6-100%. There is an increase in unilateral retinoblastoma cases leading to an increase in demand for its treatment which is expected to drive segmental growth.



North America is Expected to hold a Significant Market Share Over the Forecast Period

North America accounts for a significant market share of retinoblastoma treatment and is expected to continue its stronghold over the forecast period. This region is expected to increase its market share in the future because retinoblastoma (Rb) is the most common primary intraocular malignancy of infancy and childhood, and seriously endangers the vision and life of children.

According to an article published by the American Society of Clinical Oncology, in February 2022, retinoblastoma makes up 2% of all cancers diagnosed in children before age 15. An estimated 200 to 300 children in the United States are diagnosed with retinoblastoma each year.

Furthermore, an increase in regulatory approval for cancer treatment in the region is expected to drive the market's growth over the forecast period. For instance, in September 2022, children's hospital Los Angeles identified molecular markers to increase precision in the treatment of retinoblastoma. Such development is expected to drive market growth over the forecast period.

Therefore, the factors mentioned above are expected to drive market growth in the region during the forecast period.



Retinoblastoma Treatment Industry Overview

The retinoblastoma treatment market is moderately competitive in nature due to the presence of companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including Baxter International, Inc., GlaxoSmithKline PLC, Pfizer, Inc., Johnson & Johnson, and Novartis AG among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Remission and the Chance of Recurrence of Retinoblastoma
4.2.2 Increasing Public Awareness on Retinoblastoma
4.3 Market Restraints
4.3.1 Side Effects of Retinoblastoma Surgery and High Cost of Treatment in Developing Countries
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Treatment Type
5.1.1 Surgery
5.1.2 Radiation therapy
5.1.3 Laser Therapy
5.1.4 Cryotherapy
5.1.5 Chemotherapy
5.1.6 Bone Marrow Transplantation/Stem Cell Transplant
5.2 By Type of Retinoblastoma
5.2.1 Non-hereditary Retinoblastoma
5.2.2 Hereditary Retinoblastoma
5.3 By Type of Staging
5.3.1 Intraocular Retinoblastoma
5.3.2 Extraocular Retinoblastoma
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter International Inc.
6.1.2 Bristol-Myers Squibb Company
6.1.3 Cadila Pharmaceuticals
6.1.4 GlaxoSmithKline plc
6.1.5 Johnson & Johnson
6.1.6 Merck & Co.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Teva Pharmaceutical Industries Ltd.
6.1.10 Cellceutix Corporation
6.1.11 Icon Bioscience
6.1.12 RXi Pharmaceuticals
7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Baxter International Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cellceutix Corporation
  • Icon Bioscience
  • RXi Pharmaceuticals

Methodology

Loading
LOADING...